Detailed Narrative
Industry Scenario and Outlook
The plastic labware industry has experienced muted demand over the past 6-8 quarters. However, management noted early signs of recovery, including a rise in customer inquiries and RFQs, strengthening optimism for a broader industry revival in the second half of FY26. Despite challenges, Tarsons maintained its leadership in the domestic market and is strategically positioned to capture additional market share as demand improves.
Financial Performance Q4 & FY25
For Q4 FY25, consolidated revenues grew 7% YoY to INR 113 crores, with consolidated EBITDA increasing 22.4% YoY to INR 37 crores, and margins expanding by 420 bps to 32.9%. Standalone EBITDA for Q4 FY25 was INR 37 crores, up 9% YoY, with a margin of 39.7%. For the full year FY25, standalone revenue was INR 314 crores (up 13.3% YoY), and consolidated revenue reached INR 392 crores. Standalone adjusted EBITDA for FY25 was INR 115 crores, with a margin of 36.5%.
Strategic Investments & Capacity Expansion
Tarsons' capital expenditure program is in its final stages, aimed at boosting production capabilities and introducing new product lines, particularly in cell culture and bioprocess products. Phase 1 commercial production at the new Panchla facility is underway, with initial revenue contributions from cell culture expected by Q4 FY26 and a full-scale ramp-up in FY27-28. The radiation plant was commercialized and commissioned in late July, with commercial radiation starting in August, and the new warehouse is expected to begin operations by early July.
International Expansion & Nerbe Integration
Standalone international revenue grew 20% YoY in FY25. The acquisition of Nerbe, a European company, aims to strengthen Tarsons' international presence. Nerbe contributed INR 20 crores to Q4 FY25 consolidated revenue and INR 78 crores for FY25, but its trading-focused model results in lower EBITDA margins (7-8%). Integration of Tarsons' manufactured products through Nerbe's channels will ramp up gradually from Q1 FY26, with a full ramp-up expected next year, despite a sluggish European economy.
Domestic Market Performance
Domestic revenues grew 10% in FY25. The company is optimistic about maintaining consistent and sustainable growth in the domestic business, driven by rising industry demand and the introduction of new product categories. Tarsons continues to focus on strengthening its presence by acquiring new customers, launching new products and SKUs, and increasing wallet share among existing customers.
Capital Allocation and Debt
The consolidated net debt as of March 31, 2025, stood at INR 303 crores. Management indicated that the peak net debt for the standalone entity would be around INR 400 crores, and for the consolidated entity, it would not exceed INR 400 crores. Annual maintenance capex is projected to be between INR 10-15 crores, with specific annual expenditure at the Panchla facility around INR 7-8 crores. FY26 consolidated depreciation is expected to be in the range of INR 80-85 crores.
Future Growth Trajectory and Margins
Tarsons expects to return to its historical CAGR growth range of 16-18% in the near future. Capacity utilization is projected to reach 50-60% in about 2 years and 80-90% in 3.5-4 years. Standalone EBITDA margins, currently around 36.5-37%, could see improvements of 2-3% at peak. The peak turnover from existing and new infrastructure, without further capex, is estimated at INR 800 crores, with peak utilization turnover of INR 750-800 crores expected by FY28 or FY29.